Company / Shareholders' Equity
Zoetis Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$3.3B
FY2025
5-year range
$3.3B / $5.0B
FY2021-FY2025
Trend
-30.2%
vs FY2024
Sector context
#22 of 213
Health Care
What the data says
Among 213 Health Care companies, Zoetis is in the top 10% for shareholders' equity. Shareholders' Equity has fluctuated over the past 10 years, ranging from $1.5B in FY2016 to $5.0B in FY2023.
Based on SEC 10-K filings.
$3.3B in FY2025 with a 5-year CAGR of -2.4%. Top quartile in the Health Care sector.
Declined from $5.0B to $3.3B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -8.9%
- 5-Year CAGR
- -2.4%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 213This company $3.3B Sector average $2.5B
▼
+30.7% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.4%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 30.2% year-over-year.
- Ranks #22 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 28.2%
- Strong return on equity: 49.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.3B | -30.2% |
| FY2024 | $4.8B | -4.5% |
| FY2023 | $5.0B | +13.4% |
| FY2022 | $4.4B | -3.0% |
| FY2021 | $4.5B | +20.5% |
| FY2020 | $3.8B | +39.2% |
| FY2019 | $2.7B | +23.9% |
| FY2018 | $2.2B | +23.4% |
| FY2017 | $1.8B | +19.0% |
| FY2016 | $1.5B | +39.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026